*Naoki Hashimoto1, Norio Yasui-Furukori2, Naomi Hasegawa3, Hikaru Hori4, Hitoshi Iida4, Kayo Ichihashi5, Kenichiro Miura3, Junya Matsumoto3, Shusuke Numata6, Fumitoshi Kodaka7, Ryuji Furihata8, Ken Inada9, Koichiro Watanabe10, Ryota Hashimoto3
(1. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, 2. Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan, 3. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 4. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, 5. Department of Neuropsychiatry, University of Tokyo Hospital, Tokyo, Japan, 6. Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Tokushima, Japan, 7. Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan, 8. Agency for Student Support and Disability Resources, Kyoto University, Kyoto, Japan, 9. Department of Psychiatry, Kitasato University School of Medicine, Kanagawa, Japan, 10. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan)
Keywords:antipsychotics, polypharmacy, monotherapy, antipsychotic
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.